Inspire Medical Systems, Inc.

Inspire Medical Systems, Inc. announced it will release its second quarter 2026 financial results after the close of trading on Monday, August 3. The company's management team will host a conference call on the same day at 5:00 p.m. Eastern Time to discuss the results and recent business developments. A webcast will be available for listeners, and registration is required for those planning to ask questions.

Inspire Medical Systems, Inc. announced its participation in various meetings with investors and analysts throughout June 2026. The company has furnished the presentation materials being used at these meetings as Exhibit 99.1 to its Form 8-K filing. These materials are also accessible on the Investor Relations page of the company's website.

Inspire Medical Systems, Inc. announced that its management team will participate in the Wells Fargo 2026 MedTech Innovation Spotlight. The presentation is scheduled for Friday, June 26, 2026, at 10:00 a.m. Eastern Time. A live webcast will be available, with a replay accessible for two weeks on the company's investor website.

Inspire Medical Systems, Inc. stockholders approved significant corporate governance changes at their 2026 Annual Meeting. Key approvals included an amendment and restatement of the 2018 Incentive Award Plan, authorizing an additional 2,600,000 shares for awards and implementing stricter vesting rules. Stockholders also approved an amendment to phase out the classified board structure, moving towards annual election of all directors starting in 2029. Additionally, directors were elected, the independent auditor was ratified, and executive compensation received advisory approval.

Inspire Medical Systems reported a net loss of $(11.3) million for Q1 2026, a significant decline from a $3.0 million net income in Q1 2025, despite a slight revenue increase to $204.6 million. The company is facing multiple securities class action lawsuits and derivative lawsuits related to the Inspire V neurostimulator launch, as well as a Department of Justice civil investigative demand and a False Claims Act qui tam lawsuit. Inspire also filed a patent infringement lawsuit against Nyxoah SA.

Inspire Medical Systems reported Q1 2026 financial results, with revenue increasing 1.6% to $204.6 million and a diluted EPS of $(0.39). The company achieved improved adjusted operating income and $12.8 million in operating cash flow. However, due to ongoing coding and reimbursement uncertainty and the WISeR program, Inspire revised its full-year 2026 revenue guidance downwards to $825 million-$875 million, representing a 4%-10% decline, and adjusted operating margin to 2%-4%.

Inspire Medical Systems reported Q1 2026 financial results with revenue increasing 1.6% to $204.6 million and adjusted diluted EPS of $0.10. The company faced disruption from coding and reimbursement uncertainty and the WISeR program, which impacted growth. Consequently, Inspire Medical Systems revised its full-year 2026 revenue guidance to $825 million to $875 million, representing a 4% to 10% decline compared to 2025, and expects challenges to persist through the year.